

# **Genome Editing Market: Focus on Technology - Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Application Area, Type of End User, Key Geographical Regions and Distribution by Type of Payment Method Employed: Industry Trends and Global Forecasts, 2023-2035**

<https://marketpublishers.com/r/G6A0C9E62822EN.html>

Date: January 2024

Pages: 0

Price: US\$ 4,799.00 (Single User License)

ID: G6A0C9E62822EN

## **Abstracts**

The genome editing market is expected to reach USD 3.5 billion by 2023 anticipated to grow at a CAGR of 12.6% during the forecast period 2023-2035.

Genome editing, also known as gene editing, is a genetic engineering technique that allows for the modification of a single gene or a sequence of genes within an organism's genome. In recent years, there has been a growing need for precise genome editing, leading to the development of various tools by gene-editing companies, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR technology. These tools have been widely used to address clinical conditions resulting from genetic abnormalities, including sickle cell disease, Parkinson's disease, hearing loss, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders. Gene therapy, with over 300 candidates in clinical trials as of 2023, has emerged as a promising option. In addition, Prophylaxis treatment is another segment that has garnered significant attention in the gene editing market. However, the development of gene-edited drug products requires substantial investment in drug discovery, development, and manufacturing. To ensure the efficient, precise, and safe delivery of these drugs, pharmaceutical companies are relying on

novel genome editing technologies developed by genome editing companies. This is expected to improve the clinical outcome of therapeutics by achieving the desired genetic manipulation. With promising results in clinical trials and accelerated drug approvals, the genome editing market is projected to experience significant growth in the coming years.

## Report Coverage

The report examines genome editing market by categorizing it based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.

It evaluates the factors impacting market growth, such as drivers, restraints, opportunities, and challenges.

The report analyzes the potential benefits and barriers within the market and provides insights into the competitive landscape for leading market players.

It forecasts market segment revenues across three major regions.

Perform a comprehensive market analysis of genome editing companies, outlining essential parameters like founding year, company size in terms of workforce, headquarters location, operational model, type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application

Offer comprehensive profiles of genome editing companies, including an overview, establishment year, workforce count, headquarters location, key executives, technology portfolios, recent advancements, and future prospects.

Conduct a competitive analysis based on service tenure, competitiveness index encompassing type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.

Analyze recent partnerships within the sustainable packaging market

(2018-2023), considering partnership years, models (licensing agreements, research and development agreements, technology integration agreements, etc), partner types, active companies, agreement types, and regional distribution.

Examination of investments received by genome editing players from 2018 to 2023 details funding instances, amounts, funding types, investors, active players, active investors, and geographical distribution.

Detailed analysis of patents filed or granted in genome editing domain, considering parameters such as patent types, years, regions, applicant types, leading assignees, benchmarking, and valuation.

## Key Market Companies

Arcturus Therapeutics

Avectas

Beam Therapeutics

Bio-Sourcing

Caribou Biosciences

Century Therapeutics

CRISPR Therapeutics

EdiGene

Editas Medicine

Flash Therapeutics

Fortgen

G+FLAS Life Sciences

Graphite Bio

Intellia Therapeutics

Ntrans Technologies

OXGENE

Prime Medicine

Revvity (formerly known as Horizon Discovery)

TargetGene Biotechnologies

Vor Biopharma

ZeClinics

## Contents

### **1. PREFACE**

- 1.1. Introduction
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Frequently Asked Questions
- 1.6. Chapter Outlines

### **2. RESEARCH METHODOLOGY**

- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
  - 2.7.1. Demographics
  - 2.7.2. Economic Factors
  - 2.7.3. Government Regulations
  - 2.7.4. Supply Chain
  - 2.7.5. COVID Impact / Related Factors
  - 2.7.6. Market Access
  - 2.7.7. Healthcare Policies
  - 2.7.8. Industry Consolidation

### **3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS**

- 3.1. Chapter Overview
- 3.2. Market Dynamics
  - 3.2.1. Time Period
    - 3.2.1.1. Historical Trends
    - 3.2.1.2. Current and Forecasted Estimates
  - 3.2.2. Currency Coverage
    - 3.2.2.1. Overview of Major Currencies Affecting the Market
    - 3.2.2.2. Impact of Currency Fluctuations on the Industry

### 3.2.3. Foreign Exchange Impact

#### 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market

#### 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

### 3.2.4. Recession

#### 3.2.4.1. Historical Analysis of Past

#### Recessions and Lessons Learnt

#### 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

### 3.2.5. Inflation

#### 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

#### 3.2.5.2. Potential Impact of Inflation on the Market Evolution

## 4. EXECUTIVE SUMMARY

## 5. INTRODUCTION

### 5.1. Chapter Overview

### 5.2. Introduction to Genome Editing

#### 5.2.1. Evolution of Genome Editing

#### 5.2.2. Genome Editing Technologies

##### 5.2.2.1. CRISPR - Cas System

##### 5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)

##### 5.2.2.3. Zinc Finger Nucleases (ZFNs)

##### 5.2.2.4. Meganucleases / Homing Endonucleases

### 5.3. Applications of Genome Editing Technologies

### 5.4. Other Emerging Technologies

### 5.5. Concluding Remarks

## 6. TECHNOLOGY LANDSCAPE

### 6.1. Chapter Overview

### 6.2. Genome Editing: Technology Landscape

#### 6.2.1. Analysis by Type of Gene Editing Technique

#### 6.2.2. Analysis by Gene Editing Approach

#### 6.2.3. Analysis by Type of Gene Delivery Method

#### 6.2.4. Analysis by Type of Gene Delivery Modality

#### 6.2.5. Analysis by Highest Phase of Drug Development Supported

#### 6.2.6. Analysis by Therapeutic Area

#### 6.2.7. Analysis by Application Area

### 6.3. Genome Editing: Technology Developer Landscape

6.3.1. Analysis by Year of Establishment

6.3.2. Analysis by Company Size

6.3.3. Analysis by Location of Headquarters

6.3.4. Analysis by Operational Model

6.3.5. Most Active Players: Distribution by Number of Technologies

## 7. TECHNOLOGY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview

7.2. Assumptions / Key Parameters

7.3. Methodology

7.4. Technology Competitiveness Analysis

7.4.1. Genome Editing Technologies Offered by Players based in North America

7.4.2. Genome Editing Technologies Offered by Players based in Europe

7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America

## 8. COMPANY PROFILES

8.1. Chapter Overview

8.2. Arcturus Therapeutics

8.2.1. Company Overview

8.2.2. Financial Information

8.2.3. Technology Portfolio

8.2.4. Recent Developments and Future Outlook

8.3. Beam Therapeutics

8.3.1. Company Overview

8.3.2. Financial Information

8.3.3. Technology Portfolio

8.3.4. Recent Developments and Future Outlook

8.4. Caribou Biosciences

8.4.1. Company Overview

8.4.2. Financial Information

8.4.3. Technology Portfolio

8.4.4. Recent Developments and Future Outlook

8.5. Century Therapeutics

8.5.1. Company Overview

8.5.2. Financial Information

- 8.5.3. Technology Portfolio
- 8.5.4. Recent Developments and Future Outlook
- 8.6. CRISPR Therapeutics
  - 8.6.1. Company Overview
  - 8.6.2. Financial Information
  - 8.6.3. Technology Portfolio
  - 8.6.4. Recent Developments and Future Outlook
- 8.7. Editas Medicine
  - 8.7.1. Company Overview
  - 8.7.2. Financial Information
  - 8.7.3. Technology Portfolio
  - 8.7.4. Recent Developments and Future Outlook
- 8.8. Graphite Bio
  - 8.8.1. Company Overview
  - 8.8.2. Technology Portfolio
  - 8.8.3. Recent Developments and Future Outlook
- 8.9. Intellia Therapeutics
  - 8.9.1. Company Overview
  - 8.9.2. Financial Information
  - 8.9.3. Technology Portfolio
  - 8.9.4. Recent Developments and Future Outlook
- 8.10. Prime Medicine
  - 8.10.1. Company Overview
  - 8.10.2. Technology Portfolio
  - 8.10.3. Recent Developments and Future Outlook
- 8.11. Vor Biopharma
  - 8.11.1. Company Overview
  - 8.11.2. Technology Portfolio
  - 8.11.3. Recent Developments and Future Outlook
- 8.12. Other Leading Players
  - 8.12.1. Avectas
  - 8.12.2. Bio-Sourcing
  - 8.12.3. Edigene
  - 8.12.4. Flash Therapeutics
  - 8.12.5. Fortgen
  - 8.12.6. G+FLAS Life Sciences
  - 8.12.7. Ntrans Technologies
  - 8.12.8. OXGENE
  - 8.12.9. Revvity (formerly known as Horizon Discovery)



8.12.10. TargetGene Biotechnologies

8.12.11. ZeClinics

## **9. PARTNERSHIPS AND COLLABORATIONS**

9.1. Chapter Overview

9.2. Partnership Models

9.3. Genome Editing Technologies: Partnerships and Collaborations

9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Year and Type of Partnership

9.3.4. Analysis by Type of Partner

9.3.5. Analysis by Location of Headquarters of Partner

9.3.6. Most Active Players: Analysis by Number of Partnerships

9.3.7. Analysis by Geography

9.3.7.1. Local and International Agreements

9.3.7.2. Intercontinental and Intracontinental Agreements

## **10. PATENT ANALYSIS**

10.1. Chapter Overview

10.2. Scope and Methodology

10.3. Genome Editing Domain: Patent Analysis

10.3.1. Analysis by Publication Year

10.3.2. Analysis by Type of Patent and Publication Year

10.3.3. Analysis by Geography

10.3.4. Analysis by CPC Symbols

10.3.5. Leading Industry Players: Analysis by Number of Patents

10.4. Genome Editing Domain: Patent Benchmarking Analysis

10.4.1. Analysis by Patent Characteristics

10.4.2. Analysis by Leading Industry Players

10.5. Patent Valuation Analysis

## **11. FUNDING AND INVESTMENT ANALYSIS**

11.1. Chapter Overview

11.2. Types of Funding

11.3. Genome Editing Domain: Funding and Investment Analysis

11.3.1. Analysis by Year of Investment

- 11.3.1.1. Cumulative Year-wise Trend of Funding Instances
- 11.3.1.2. Cumulative Year-wise Trend of Amount Invested
- 11.3.2. Analysis by Type of Funding
  - 11.3.2.1. Analysis of Funding Instances
  - 11.3.2.2. Analysis of Amount Invested
- 11.3.3. Analysis by Year and Type of Funding
- 11.3.4. Analysis by Geography
- 11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
- 11.3.6. Leading Investors: Analysis by Number of Funding Instances

## **12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES**

- 12.1. Chapter Overview
- 12.2. Market Drivers
- 12.3. Market Restraints
- 12.4. Market Opportunities
- 12.5. Market Challenges
- 12.6. Conclusion

## **13. GENOME EDITING TECHNOLOGIES MARKET**

- 13.1. Chapter Overview
- 13.2. Assumptions and Methodology
- 13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
  - 13.3.1. Scenario Analysis
- 13.4. Key Market Segmentations
- 13.5. Dynamic Dashboard

## **14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE**

- 14.1. Chapter Overview
- 14.2. Key Assumptions and Methodology
- 14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
- 14.4. TALENs: Forecasted Estimates (2023-2035)
- 14.5. Meganucleases: Forecasted Estimates (2023-2035)
- 14.6. ZFNs: Forecasted Estimates (2023-2035)

14.7. Other Techniques: Forecasted Estimates (2023-2035)

14.8. Data Triangulation

14.8.1. Insights from Primary Research

14.8.2. Insights from Secondary Research

14.8.3. Insights from In-house Repository

## **15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY**

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Cell Therapies: Forecasted Estimates (2023-2035)

15.4. Gene Therapies: Forecasted Estimates (2023-2035)

15.5. Other Therapies: Forecasted Estimates (2023-2035)

15.6. Data Triangulation

15.6.1. Insights from Primary Research

15.6.2. Insights from Secondary Research

15.6.3. Insights from In-house Repository

## **16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH**

16.1. Chapter Overview

16.2. Key Assumptions and Methodology

16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)

16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)

16.5. Data Triangulation

16.5.1. Insights from Primary Research

16.5.2. Insights from Secondary Research

16.5.3. Insights from In-house Repository

## **17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD**

17.1. Chapter Overview

17.2. Key Assumptions and Methodology

17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)

17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)

17.5. Data Triangulation

17.5.1. Insights from Primary Research

17.5.2. Insights from Secondary Research

17.5.3. Insights from In-house Repository

## **18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY**

- 18.1. Chapter Overview
- 18.2. Key Assumptions and Methodology
- 18.3. Viral Vectors: Forecasted Estimates (2023-2035)
- 18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
- 18.5. Data Triangulation
  - 18.5.1. Insights from Primary Research
  - 18.5.2. Insights from Secondary Research
  - 18.5.3. Insights from In-house Repository

## **19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA**

- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
- 19.4. Diagnostics: Forecasted Estimates (2023-2035)
- 19.5. Data Triangulation
  - 19.5.1. Insights from Primary Research
  - 19.5.2. Insights from Secondary Research
  - 19.5.3. Insights from In-house Repository

## **20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER**

- 20.1. Chapter Overview
- 20.2. Key Assumptions and Methodology
- 20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
- 20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
- 20.5. Data Triangulation
  - 20.5.1. Insights from Primary Research
  - 20.5.2. Insights from Secondary Research
  - 20.5.3. Insights from In-house Repository

## **21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS**

- 21.1. Chapter Overview
- 21.2. Key Assumptions and Methodology
- 21.3. North America: Forecasted Estimates (2023-2035)
- 21.4. Europe: Forecasted Estimates (2023-2035)
- 21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
- 21.6. Data Triangulation
  - 21.6.1. Insights from Primary Research
  - 21.6.2. Insights from Secondary Research
  - 21.6.3. Insights from In-house Repository

## **22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED**

- 22.1. Chapter Overview
- 22.2. Key Assumptions and Methodology
- 22.3. Milestone Payments: Forecasted Estimates (2023-2035)
- 22.4. Upfront Payments: Forecasted Estimates (2023-2035)
- 22.5. Data Triangulation
  - 22.5.1. Insights from Primary Research
  - 22.5.2. Insights from Secondary Research
  - 22.5.3. Insights from In-house Repository

## **23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS**

- 23.1. Chapter Overview
- 23.2. Leading Industry Players

## **24. CONCLUSION**

## **25. EXECUTIVE INSIGHTS**

## **26. APPENDIX 1: TABULATED DATA**

## **27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS**

## I would like to order

Product name: Genome Editing Market: Focus on Technology - Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Application Area, Type of End User, Key Geographical Regions and Distribution by Type of Payment Method Employed: Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/G6A0C9E62822EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6A0C9E62822EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970